Skip to main content
SpringerLink
Log in

Control of Osteoclast Activity and Bone Loss by IKK Subunits: New Targets for Therapy

  • Conference paper
Osteoimmunology

Part of the book series: Advances in Experimental Medicine and Biology ((volume 602))

Transcription factor NF-κB has been well recognized as a pivotal player in osteclastogenesis and inflammation-induced bone loss. Here, we discuss our recent results obtained using a genetic approach in mice that indicate the importance of IKKβ, and not IKKα, as a transducer of signals from receptor activator of NF-κB (RANK) to NF-κB. Ablation of IKKβ results in lack of osteoclastogenesis and unresponsiveness of IKKβ-deficient mice to inflammation-induced bone loss. In the need of a more effective therapy for the treatment of inflammatory diseases causing bone resorption, specific inhibition of IKKβ represents a logical alternative strategy to the current therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abu-Amer, Y., J. Erdmann, et al. 2000. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 275(35): 27307–27310.

    CAS  PubMed  Google Scholar 

  • Barnes, P.J., and M. Karin. 1997. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336(15): 1066–1071.

    Article  CAS  PubMed  Google Scholar 

  • Bathon, J.M., R.W. Martin, et al. 2000. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343(22): 1586–1593.

    Article  CAS  PubMed  Google Scholar 

  • Bolon, B., G. Campagnuolo, et al. 2002. Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. Cell Mol Life Sci 59(9): 1569–1576.

    Article  CAS  PubMed  Google Scholar 

  • Bonizzi, G., and M. Karin. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25(6): 280–288.

    Article  CAS  PubMed  Google Scholar 

  • Boyle, W.J., W.S. Simonet, et al. 2003. Osteoclast differentiation and activation. Nature 423(6937): 337–342.

    Article  CAS  PubMed  Google Scholar 

  • Breedveld, F.C., P. Emery, et al. 2004. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63(2): 149–155.

    Article  CAS  PubMed  Google Scholar 

  • Campagnuolo, G., B. Bolon, et al. 2002. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum 46(7): 1926–1936.

    Article  CAS  PubMed  Google Scholar 

  • Campbell, I.K., S. Gerondakis, et al. 2000. Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest 105(12): 1799–1806.

    Article  CAS  PubMed  Google Scholar 

  • Campbell, I.K., K. O’Donnell, et al. 2001. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest 107(12): 1519–1527.

    Article  CAS  PubMed  Google Scholar 

  • Chellaiah, M., C. Fitzgerald, et al. 1998. c-Src is required for stimulation of gelsolin-associated phosphatidylinositol 3-kinase. J Biol Chem 273(19): 11908–11916.

    Article  CAS  PubMed  Google Scholar 

  • Danning, C.L., G.G. Illei, et al. 2000. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 43(6): 1244–1256.

    Article  CAS  PubMed  Google Scholar 

  • den Broeder, A., L. van de Putte, et al. 2002. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29(11): 2288–2298.

    Google Scholar 

  • den Broeder, A.A., L.A. Joosten, et al. 2002. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 61(4): 311–318.

    Article  Google Scholar 

  • Dougall, W.C., M. Glaccum, et al. 1999. RANK is essential for osteoclast and lymph node development. Genes Dev 13(18): 2412–2424.

    Article  CAS  PubMed  Google Scholar 

  • Duong, L.T., P.T. Lakkakorpi, et al. 1998. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v) beta3 integrin, and phosphorylated by src kinase. J Clin Invest 102(5): 881–892.

    Article  CAS  PubMed  Google Scholar 

  • Elliott, M.J., R.N. Maini, et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344(8930): 1105–1110.

    Article  CAS  PubMed  Google Scholar 

  • Epinat, J.C., and T. D. Gilmore. 1999. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene 18(49): 6896–6909.

    Article  CAS  PubMed  Google Scholar 

  • Foxwell, B., K. Browne, et al. 1998. Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci U S A 95(14): 8211–8215.

    Article  CAS  PubMed  Google Scholar 

  • Franzoso, G., L. Carlson, et al. 1997. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11(24): 3482–3496.

    Article  CAS  PubMed  Google Scholar 

  • Genovese, M.C., J.M. Bathon, et al. 2002. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46(6): 1443–1450.

    Article  CAS  PubMed  Google Scholar 

  • Ghosh, S., M.J. May, et al. 1998. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225–260.

    Article  CAS  PubMed  Google Scholar 

  • Gravallese, E.M., 2002. Bone destruction in arthritis. Ann Rheum Dis 61(Suppl 2): ii84–ii86.

    PubMed  Google Scholar 

  • Hsu, H., H.B. Shu, et al. 1996. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84(2): 299–308.

    Article  CAS  PubMed  Google Scholar 

  • Hu, Y., V. Baud, et al. 1999. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science 284(5412): 316–320.

    Article  CAS  PubMed  Google Scholar 

  • Hu, Y., V. Baud, et al. 2001. IKKalpha controls formation of the epidermis independently of NF-kappaB. Nature 410(6829): 710–714.

    Article  CAS  PubMed  Google Scholar 

  • Iotsova, V., J. Caamano, et al. 1997. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 3(11): 1285–1289.

    Article  CAS  PubMed  Google Scholar 

  • Ji, H., A. Pettit, et al. 2002. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 196(1): 77–85.

    Article  CAS  PubMed  Google Scholar 

  • Jimi, E., K. Aoki, et al. 2004. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 10(6): 617–624.

    Article  CAS  PubMed  Google Scholar 

  • Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18: 621–663.

    Article  CAS  PubMed  Google Scholar 

  • Karin, M., and A. Lin. 2002. NF-kappaB at the crossroads of life and death. Nat Immunol 3(3): 221–227.

    Article  CAS  PubMed  Google Scholar 

  • Karsenty, G., and E.F. Wagner. 2002. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2(4): 389–406.

    Article  CAS  PubMed  Google Scholar 

  • Kobayashi, K., N. Takahashi, et al. 2000. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191(2): 275–286.

    Article  CAS  PubMed  Google Scholar 

  • Kong, Y.Y., U. Feige, et al. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402(6759): 304–309.

    Article  CAS  PubMed  Google Scholar 

  • Kong, Y.Y., H. Yoshida, et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397(6717): 315–323.

    Article  CAS  PubMed  Google Scholar 

  • Kremer, J.M., M.E. Weinblatt, et al. 2003. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 48(6): 1493–1499.

    Article  CAS  PubMed  Google Scholar 

  • Lacey, D.L., E. Timms, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93(2): 165–176.

    Article  CAS  PubMed  Google Scholar 

  • Lam, J., S. Takeshita, et al. 2000. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106(12): 1481–1488.

    Article  CAS  PubMed  Google Scholar 

  • Lawrence, T., D.A. Willoughby, et al. 2002. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2(10): 787–795.

    Article  CAS  PubMed  Google Scholar 

  • Lee, S.E., K.M. Woo, et al. 2002. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 30(1): 71–77.

    Article  CAS  PubMed  Google Scholar 

  • Leisen, J.C., H. Duncan, et al. 1988. The erosive front: a topographic study of the junction between the pannus and the subchondral plate in the macerated rheumatoid metacarpal head. J Rheumatol 15(1): 17–22.

    CAS  PubMed  Google Scholar 

  • Li, Q., D. Van Antwerp, et al. 1999. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 284(5412): 321–325.

    Article  CAS  PubMed  Google Scholar 

  • Li, Z.W., W. Chu, et al. 1999. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 189(11): 1839–1845.

    Article  CAS  PubMed  Google Scholar 

  • Lipsky, P.E., D.M. van der Heijde, et al. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343(22): 1594–1602.

    Article  CAS  PubMed  Google Scholar 

  • Liu, Z.G., H. Hsu, et al. 1996. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87(3): 565–576.

    Article  CAS  PubMed  Google Scholar 

  • MacNaul, K.L., N.I. Hutchinson, et al. 1990. Analysis of IL-1 and TNF-alpha gene expression in human rheumatoid synoviocytes and normal monocytes by in situ hybridization. J Immunol 145(12): 4154–4166.

    CAS  PubMed  Google Scholar 

  • Maeda, S., L. Chang, et al. 2003. IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity 19(5): 725–737.

    Article  CAS  PubMed  Google Scholar 

  • Maini, R., E.W. St. Clair, et al. 1999. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194): 1932–1939.

    Article  CAS  PubMed  Google Scholar 

  • Maini, R.N., F.C. Breedveld, et al. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9): 1552–1563.

    Article  CAS  PubMed  Google Scholar 

  • Mercurio, F., H. Zhu, et al. 1997. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 2785339: 860–866.

    Article  Google Scholar 

  • Miagkov, A.V., D.V. Kovalenko, et al. 1998. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci U S A 95(23): 13859–13864.

    Article  CAS  PubMed  Google Scholar 

  • Moreland, L.W., S.W. Baumgartner, et al. 1997. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337(3): 141–7.

    Article  CAS  PubMed  Google Scholar 

  • Moreland, L.W., M.H. Schiff, et al. 1999. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130(6): 478–486.

    CAS  PubMed  Google Scholar 

  • Mostov, K., and Z. Werb (1997). Journey across the osteoclast. Science 276(5310): 219–220.

    Article  CAS  PubMed  Google Scholar 

  • Nakashima, T., T. Wada, et al. 2003. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 15(3): 280–287.

    Article  CAS  PubMed  Google Scholar 

  • Novack, D.V., L. Yin, et al. 2003. The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J Exp Med 198(5): 771–781.

    Article  CAS  PubMed  Google Scholar 

  • Pettit, A.R., H. Ji, et al. 2001. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159(5): 1689–1699.

    CAS  PubMed  Google Scholar 

  • Reddi, A.H. 1997. Bone morphogenesis and modeling: soluble signals sculpt osteosomes in the solid state. Cell 89(2): 159–161.

    Article  CAS  PubMed  Google Scholar 

  • Redlich, K., S. Hayer, et al. 2002. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110(10): 1419–1427.

    CAS  PubMed  Google Scholar 

  • Romas, E., N.A. Sims, et al. 2002. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 161(4): 1419–1427.

    CAS  PubMed  Google Scholar 

  • Roodman, G.D. 1999. Cell biology of the osteoclast. Exp Hematol 27(8): 1229–1241.

    Article  CAS  PubMed  Google Scholar 

  • Rothwarf, D.M., and M. Karin. 1999. The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE 1999(5): RE1.

    Google Scholar 

  • Ruocco, M.G., S. Maeda, et al. 2005. I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 201(10): 1677–1687.

    Article  CAS  PubMed  Google Scholar 

  • Sato, T., C. Selleri, et al. 1997. Expression and modulation of cellular receptors for interferon-gamma, tumour necrosis factor, and Fas on human bone marrow CD34+ cells. Br J Haematol 97(2): 356–365.

    Article  CAS  PubMed  Google Scholar 

  • Schett, G., K. Redlich, et al. 2003. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 48(7): 2042–2051.

    Article  CAS  PubMed  Google Scholar 

  • Seetharaman, R., A.L. Mora, et al. 1999. Essential role of T cell NF-kappa B activation in collagen-induced arthritis. J Immunol 163(3): 1577–1583.

    CAS  PubMed  Google Scholar 

  • Senftleben, U., Y. Cao, et al. 2001. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293(5534): 1495–1499.

    Article  CAS  PubMed  Google Scholar 

  • Senftleben, U., Z.W. Li, et al. 2001. IKKbeta is essential for protecting T cells from TNFalpha-induced apoptosis. Immunity 14(3): 217–230.

    Article  CAS  PubMed  Google Scholar 

  • Shealy, D.J., P.H. Wooley, et al. 2002. Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res 4(5): R7.

    Article  PubMed  Google Scholar 

  • Shinkura, R., K. Kitada, et al. 1999. Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase. Nat Genet 22(1): 74–77.

    Article  CAS  PubMed  Google Scholar 

  • Simonet, W.S., D.L. Lacey, et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89(2): 309–319.

    Article  CAS  PubMed  Google Scholar 

  • Soriano, P., C. Montgomery, et al. 1991. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64(4): 693–702.

    Article  CAS  PubMed  Google Scholar 

  • Suzuki, Y., F. Nishikaku, et al. 1998. Osteoclast-like cells in murine collagen induced arthritis. J Rheumatol 25(6): 1154–1160.

    CAS  PubMed  Google Scholar 

  • Tak, P.P., and G.S. Firestein. 2001. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107(1): 7–11.

    Article  CAS  PubMed  Google Scholar 

  • Tanaka, S., M. Amling, et al. 1996. c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature 383(6600): 528–531.

    Article  CAS  PubMed  Google Scholar 

  • Weinblatt, M.E., E.C. Keystone, et al. 2003. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1): 35–45.

    Article  CAS  PubMed  Google Scholar 

  • Weinblatt, M.E., J.M. Kremer, et al. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340(4): 253–259.

    Article  CAS  PubMed  Google Scholar 

  • Wong, B.R., D. Besser, et al. 1999. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 4(6): 1041–1049.

    Article  CAS  PubMed  Google Scholar 

  • Zandi, E., D.M. Rothwarf, et al. 1997. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91(2): 243–252.

    Article  CAS  PubMed  Google Scholar 

  • Zhang, Y.H., A. Heulsmann, et al. 2001. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 276(1): 563–568.

    Article  CAS  PubMed  Google Scholar 

  • Zou, W., I. Hakim, et al. 2001. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem 83(1): 70–83.

    Article  CAS  PubMed  Google Scholar 

  • Zwerina, J., S. Hayer, et al. 2004. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 50(1): 277–290.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Gene Regulation and Signal Transduction, University of California, San Diego, 92093, 9500 Gilman Drive, La Jolla, CA, USA

    Maria Grazia Ruocco & Michael Karin

Authors
  1. Maria Grazia Ruocco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Karin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 19104, Philadelphia, PA, USA

    Yongwon Choi

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this paper

Cite this paper

Ruocco, M.G., Karin, M. (2007). Control of Osteoclast Activity and Bone Loss by IKK Subunits: New Targets for Therapy. In: Choi, Y. (eds) Osteoimmunology. Advances in Experimental Medicine and Biology, vol 602. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-72009-8_16

Download citation

Publish with us

Policies and ethics

Search

Navigation